Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Patiromer

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 407Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Veltassa Approved In Japan For Adult Hyperkalemia Treatment
    Veltassa Approved In Japan For Adult Hyperkalemia Treatment

    23 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/veltassa-patiromer-approved-in-japan-for-the-treatment-of-adults-with-hyperkalemia-302256749.html

    PR NEWSWIRE
    23 Sep 2024
    Share Share
    Vifor's hyperkalaemia drug Veltassa shows benefit in heart failure patients
    Vifor's hyperkalaemia drug Veltassa shows benefit in heart failure patients

    21 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211220005646/en/Vifor-Pharma-reports-positive-outcome-of-the-phase-IIIb-DIAMOND-trial-of-Veltassa%C2%AE

    BUSINESSWIRE
    21 Dec 2021
    Share Share
    Vifor reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa
    Vifor reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa

    20 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211220005646/en

    BUSINESSWIRE
    20 Dec 2021
    Share Share
    Vifor's Ferinject® granted new recommendations in ESC heart failure guidelines
    Vifor's Ferinject® granted new recommendations in ESC heart failure guidelines

    31 Aug 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210830005519/en

    BUSINESSWIRE
    31 Aug 2021
    Share Share
    NICE reverses previous decision to recommend Vifor Pharma's Veltassa for NHS
    NICE reverses previous decision to recommend Vifor Pharma's Veltassa for NHS

    16 Dec 2019

    // PHARMAFILE

    http://www.pharmafile.com/news/535799/nice-reverses-previous-decision-recommend-vifor-pharmas-veltassa-nhs-treatment-hyperkala

    PHARMAFILE
    16 Dec 2019
    Share Share
    Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint
    Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint

    13 May 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190510005469/en/Vifor-Pharma%E2%80%99s-Phase-II-AMBER-Study-Meets-Primary/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    BUSINESSWIRE
    13 May 2019
    Share Share